<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657265</url>
  </required_header>
  <id_info>
    <org_study_id>EU2014-09</org_study_id>
    <nct_id>NCT02657265</nct_id>
  </id_info>
  <brief_title>SpineJack® Versus Conservative Treatment Study (SPICO Study)</brief_title>
  <official_title>Prospective Multicenter Randomized Study Comparing Two Standard Treatments: SpineJack® System and Conservative Orthopedic Management in Acute Traumatic Vertebral Fractures Types A1 and A3.1 According to the Magerl Classification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vexim SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Statitec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vexim SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare two standard treatments in acute stable traumatic vertebral fractures&#xD;
      (types A1 and A3.1 by Magerl Classification). The two treatments are as follows:&#xD;
&#xD;
        1. SpineJack® system&#xD;
&#xD;
        2. Conservative Orthopedic Management consisting of brace and pain medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 subjects (18 to 60 years old) will be enrolled (1:1) with one to two painful traumatic&#xD;
      fractures, non-pathological (types A1 and A3.1 by Magerl Classification).&#xD;
&#xD;
      Subjects will be followed at admission, procedure, discharge, 1 month, 3 months, 12 months&#xD;
      and 24 months post Vertebral Compression Fracture (VCF) reduction procedure or the set-up of&#xD;
      the brace.&#xD;
&#xD;
      The estimated enrollment period is 12 months and each patient should perform a 24 months&#xD;
      follow-up period. Therefore, the total study duration is estimated to be 36 months for the&#xD;
      complete study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2016</start_date>
  <completion_date type="Actual">May 14, 2020</completion_date>
  <primary_completion_date type="Actual">May 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS</measure>
    <time_frame>Mean Visual Analogue Scale (VAS) back pain score: change from baseline to 12 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>Screening/baseline, immediat post-op, 1, 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Screening/baseline, immediat post-op, 1, 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kyphotic angle</measure>
    <time_frame>Screening/baseline, immediat post-op, 1, 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Kyphotic Angle</measure>
    <time_frame>Screening/baseline, immediat post-op, 1, 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety through evaluation of adverse events</measure>
    <time_frame>Screening/baseline, immediat post-op, 1, 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs comparison of overall treatments</measure>
    <time_frame>Screening/baseline, immediat post-op, 1, 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Spinal Fractures</condition>
  <condition>Vertebral Compression Fractures</condition>
  <condition>Back Injuries</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>SpineJack® system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spine fracture management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical corset according to measurement's impression, rigid corset with sternal support</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpineJack system</intervention_name>
    <description>Spine fracture management for traumatic vertebral compression fracture</description>
    <arm_group_label>SpineJack® system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conservative management</intervention_name>
    <description>Surgical corset according to measurement's impression, rigid corset with sternal support</description>
    <arm_group_label>Conservative management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have signed the consent form&#xD;
&#xD;
          2. Male or Female between 18 and 60 years old&#xD;
&#xD;
          3. One to two painful traumatic fractures, non-pathological, traumatic vertebral fracture&#xD;
             is less than 10 days, between T11 and L5, type A1 and A3.1 according to Magerl&#xD;
             classification. All the fractures should meet the inclusion criteria (deformity,&#xD;
             etiology, technical possibility of performing the procedure).&#xD;
&#xD;
          4. Vertebral kyphosis angle &gt;10°&#xD;
&#xD;
          5. Patient is eligible to treatment with brace&#xD;
&#xD;
          6. Technical feasibility of a SpineJack® procedure and brace 1 to 5 days after&#xD;
             screening/baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Vertebral fracture more than 10 days old&#xD;
&#xD;
          2. Spontaneous osteoporotic vertebral fracture&#xD;
&#xD;
          3. Neurological signs or symptoms related to the vertebral fracture&#xD;
&#xD;
          4. Vertebral kyphosis angle &gt;30°&#xD;
&#xD;
          5. Active systemic or local infection at baseline&#xD;
&#xD;
          6. Patient with substance abuse&#xD;
&#xD;
          7. History of intolerance or allergic reaction to titanium or acrylic compounds&#xD;
&#xD;
          8. Fracture geometry making the insertion of the implant impossible&#xD;
&#xD;
          9. Malignant lesions&#xD;
&#xD;
         10. Any other medical illness or condition that, in the investigator's opinion, is likely&#xD;
             to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery*&#xD;
&#xD;
         11. Patient on long-term steroid therapy (steroid dose ≥ 30 mg /day for &gt; 3 months)&#xD;
&#xD;
         12. Patient presenting with a non-correctable spontaneous or therapeutic coagulation&#xD;
             disorder.&#xD;
&#xD;
         13. Non-compliant patient: Impossibility to participate in the study and to be followed-up&#xD;
             for 2 years.&#xD;
&#xD;
         14. Participating in any other investigational study&#xD;
&#xD;
         15. Female patients who are pregnant, breastfeeding, or planning to get pregnant during&#xD;
             the course of the study&#xD;
&#xD;
         16. Patient not affiliated to social security *: including but not limited to patients&#xD;
             with contraindications for general anesthesia (surgeon expertise)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Vital, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Pellegrin - Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Jean Minjoz Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Chambéry</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM, Hopital Nord Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen-Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Privé Saint Grégoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Compression</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
    <mesh_term>Back Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

